
Second patient death reported with gene therapy for muscular dystrophy
Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. The biotech drugmaker said Sunday it was pausing shipments of the drug for patients who are no longer able to walk. The one-time treatment is the first gene therapy approved in the U.S. for the rare muscle-wasting condition. The company has faced scrutiny since its accelerated approval in 2023. Sarepta says it will pause a study of the therapy and assemble an expert panel to recommend new safety protocols for taking the drug.